Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

• Conditions: JAK2 Mutation; Myeloproliferative Neoplasm; Gastroesophageal Varices
• Interventions: Drug: Anticoagulation Agents

• Registration Number: NCT04527666
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-08
• Study First Submitted: 2020-08-23
• Study First Submitted QC: 2020-08-23
• Last Update Submitted: 2020-08-25
• Study First Posted: 2020-08-26
• Last Update Posted: 2020-08-27
• Study Start: 2020-10-01
• Primary Completion: 2021-09-30
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Male or female patients aged 18-75
• diagnosed as portal hypertension by contrast-enhanced computed tomography
• diagnosed as JAK2 positive

Exclusion Criteria

• not had portal contrast-enhanced computed tomography
• not had JAK2 mutation test
• other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Anticoagulation group	Anticoagulation Agents	Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.

Primary Outcome Measures

Name	Time	Method
Changes of portal vein thrombosis	1 year	The changes of portal vein thrombosis including progression, disappear or unchanged.

Secondary Outcome Measures

Name	Time	Method
Overall survival	1 year	Overall survival rate
The occurrence of variceal bleeding	1 year	The occurrence of variceal bleeding including haematemesis and melena